Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

被引：6
作者：
Najim, Omar [1 ,2 ]
Papadimitriou, Konstantinos [1 ,2 ,3 ]
Broeckx, Glenn [1 ,2 ,4 ]
Huizing, Manon [2 ,5 ]
Tjalma, Wiebren [1 ,2 ,6 ]
机构：
[1] Univ Antwerp, Univ Antwerp Hosp, Multidisciplinary Breast Clin, Edegem, Belgium
[2] Univ Antwerp, Fac Med, Edegem, Belgium
[3] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium
[4] Antwerp Univ Hosp, Dept Pathol, Edegem, Belgium
[5] Antwerp Univ Hosp, Biobank, Edegem, Belgium
[6] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Edegem, Belgium
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
ESR1; liquid biopsy; next-generation sequencing; digital PCR; metastasized breast cancer; CIRCULATING TUMOR DNA; ACTIVATING ESR1 MUTATIONS; ACQUIRED-RESISTANCE; PLASMA; EVOLUTION; EMERGENCE; THERAPY;
D O I：
10.3389/fonc.2023.1221773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
引用
收藏
页数：12
相关论文
共 60 条
[1]   Circulating Tumor Cells: Liquid Biopsy of Cancer [J].
Alix-Panabieres, Catherine ;
Pantel, Klaus .
CLINICAL CHEMISTRY, 2013, 59 (01) :110-118
[2]   ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients [J].
Angus, Lindsay ;
Beije, Nick ;
Jager, Agnes ;
Martens, John W. M. ;
Sleijfer, Stefan .
CANCER TREATMENT REVIEWS, 2017, 52 :33-40
[3]   The Implications of Clonal Genome Evolution for Cancer Medicine [J].
Aparicio, Samuel ;
Caldas, Carlos .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (09) :842-851
[4]   Estrogen receptor (ESR1) mutation in bone metastases from breast cancer [J].
Bartels, Stephan ;
Christgen, Matthias ;
Luft, Angelina ;
Persing, Sascha ;
Joedecke, Kai ;
Lehmann, Ulrich ;
Kreipe, Hans .
MODERN PATHOLOGY, 2018, 31 (01) :56-61
[5]   Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer [J].
Beaver, Julia A. ;
Jelovac, Danijela ;
Balukrishna, Sasidharan ;
Cochran, Rory L. ;
Croessmann, Sarah ;
Zabransky, Daniel J. ;
Wong, Hong Yuen ;
Toro, Patricia Valda ;
Cidado, Justin ;
Blair, Brian G. ;
Chu, David ;
Burns, Timothy ;
Higgins, Michaela J. ;
Stearns, Vered ;
Jacobs, Lisa ;
Habibi, Mehran ;
Lange, Julie ;
Hurley, Paula J. ;
Lauring, Josh ;
VanDenBerg, Dustin A. ;
Kessler, Jill ;
Jeter, Stacie ;
Samuels, Michael L. ;
Maar, Dianna ;
Cope, Leslie ;
Cimino-Mathews, Ashley ;
Argani, Pedram ;
Wolff, Antonio C. ;
Park, Ben Ho .
CLINICAL CANCER RESEARCH, 2014, 20 (10) :2643-2650
[6]   Prognostic effect of estrogen receptor status across age in primary breast cancer [J].
Bentzon, Niels ;
Duering, Maria ;
Rasmussen, Birgitte Bruun ;
Mouridsen, Henning ;
Kroman, Niels .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (05) :1089-1094
[7]  
Bidard FC, 2020, J CLIN ONCOL, V38
[8]   Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial [J].
Bidard, Francois-Clement ;
Kaklamani, Virginia G. ;
Neven, Patrick ;
Streich, Guillermo ;
Montero, Alberto J. ;
Forget, Frederic ;
Mouret-Reynier, Marie-Ange ;
Sohn, Joo Hyuk ;
Taylor, Donatienne ;
Harnden, Kathleen K. ;
Khong, Hung ;
Kocsis, Judit ;
Dalenc, Florence ;
Dillon, Patrick M. ;
Babu, Sunil ;
Waters, Simon ;
Deleu, Ines ;
Saenz, Jose A. Garcia ;
Bria, Emilio ;
Cazzaniga, Marina ;
Lu, Janice ;
Aftimos, Philippe ;
Cortes, Javier ;
Liu, Shubin ;
Tonini, Giulia ;
Laurent, Dirk ;
Habboubi, Nassir ;
Conlan, Maureen G. ;
Bardia, Aditya .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) :3246-+
[9]   Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer [J].
Board, Ruth E. ;
Wardley, Andrew M. ;
Dixon, J. Michael ;
Armstrong, Anne C. ;
Howell, Sacha ;
Renshaw, Lorna ;
Donald, Emma ;
Greystoke, Alastair ;
Ranson, Malcolm ;
Hughes, Andrew ;
Dive, Caroline .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (02) :461-467
[10]   ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer [J].
Brett, Jamie O. ;
Spring, Laura M. ;
Bardia, Aditya ;
Wander, Seth A. .
BREAST CANCER RESEARCH, 2021, 23 (01)
123456